BioTuesdays

Category - Markets

Irwin Naturals Logo
Markets

Cantor starts Irwin Naturals at OW; PT $7

Cantor Fitzgerald initiated coverage of Irwin Naturals (OTCQB:IWINF) with and “overweight” rating and a December 2023 price target of $7. The stock closed at $1.51 on Oct. 3. Irwin Naturals, a company with a 28-year...

October 4, 2022
Clene Logo
Markets

Clene shares down 29% after Phase 2 ALS trial fails

Shares of Clene (NASDAQ:CLNN) tumbled 29% after its lead drug candidate, CNM-Au8, an investigational gold nanocrystal suspension, missed key endpoints in a platform study in amyotrophic lateral sclerosis (ALS), a...

October 3, 2022
Fennec Pharmaceuticals Logo
Markets

Maxim ups Fennec PT to $15 on PEDMARK approval

Maxim Group raised its price target for Fennec Pharmaceuticals (NASDAQ:FENC) to $15 from $10, and maintained its “buy” rating, after FDA approval of PEDMARK, its formulation of sodium thiosulfate for the prevention of...

September 29, 2022
Cognition Logo
Markets

Cantor starts Cognition at OW; PT $12

Cantor Fitzgerald launched coverage of Cognition Therapeutics (NASDAQ:CGTX) with an “overweight” rating and 12-month price target of $12. The stock closed at $1.74 on Sept. 28. Cognition is a neuro-innovator leveraging...

September 29, 2022
Akouos
Markets

WB starts Akouos at OP; fair value estimate $12

William Blair launched coverage of Akouos (NASDAQ:AKUS) with an “outperform” rating and fair value estimate of $12. The stock closed at $5.10 on Sept. 28. Akouos is developing a pipeline of gene therapies delivered...

September 29, 2022
Everest Medicines Logo
Markets

HCW starts Everest Medicines at buy; PT $30 HK

H.C. Wainwright launched coverage of Everest Medicines (HKSE:1952.HK) with a “buy” rating and price target of $30 HK. The stock closed at $10.38 HK on Sept. 8. Everest Medicines is an integrated biopharmaceutical...

September 9, 2022
Annexon Logo
Markets

BTIG starts Annexon at buy; PT $15

BTIG initiated coverage of Annexon (NASDAQ:ANNX) with a “buy” rating and $15 price target. The stock closed at $6.02 on Sept. 8. Annexon, Inc. is a development-stage biotech company focused on mediating the role of...

September 9, 2022